News Sentiment

DXR sentiment intelligence

Daxor Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Weighted score 58 Balanced news tone 35 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 10.53 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.4% over one week, +13.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.4% Price digesting
Trend fit Trend inactive 13.7% over four weeks
Fair value 8.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 23
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingKey 5
Finviz 4
Quartr 4
dars.gov.et 3
Investing.com 2
富途牛牛 1
Investing.com South Africa 1

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 7
Regulatory and legal 4
Guidance 1
Analyst action 1
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 35
Investing.com Direct company coverage

Daxor to exhibit blood volume analyzer at dysautonomia conference

Daxor Corporation announced its first-time exhibition at the 14th Annual Dysautonomia International Conference to showcase its FDA-cleared Blood Volume Analyzer (BVA). The company anticipates significant sales growth, with revenue projected to increase over 400% in fiscal 2026 du

Tone
Positive 72/100
Event
Earnings
Published
08 Jul 2026 02:10
Source
Investing.com
Stock Titan Direct company coverage

Daxor debuts Blood Volume Analyzer at dysautonomia conference

Daxor Corporation (DXR) will exhibit its FDA-cleared, next-generation Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference in July 2026. The company aims to demonstrate how objective plasma and red blood cell volume data from the

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 12:10
Source
Stock Titan
Finviz Direct company coverage

DXR - Daxor Corp Forecast, Target Price

This article provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, key financial ratios, and performance metrics. It lists various financial data points such as P/E, P/S, ROA, ROE, and percentage changes over differen

Tone
Positive 67/100
Event
Guidance
Published
04 Jul 2026 12:39
Source
Finviz
Finviz Direct company coverage

DXR - Daxor Corp Earnings

This article provides a detailed financial overview of Daxor Corp (DXR), including key metrics such as market capitalization, P/E ratio, sales, and employee data. It also covers performance indicators like EPS growth, insider and institutional ownership, and various profitability

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 05:10
Source
Finviz
Finviz Direct company coverage

DXR - Daxor Corp Options

This page provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, performance metrics over different periods, and analyst r

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 00:40
Source
Finviz
Stock Titan Direct company coverage

Daxor (DXR) CFO receives 12,000-share stock grant, now holds 33,050

Daxor Corp's CFO, Michel Robert J, received a compensation-related grant of 12,000 shares of Daxor Common Stock with no purchase price. These shares are scheduled to vest on June 23, 2026. Following this transaction, his direct holdings in the company's common stock total 33,050

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:10
Source
Stock Titan
Stock Titan Direct company coverage

Daxor (DXR) Chief Scientific Officer receives 25,000-share stock grant

Daxor's Chief Scientific Officer, Jonathan Adam Feldschuh, received a grant of 25,000 shares of Daxor common stock. This equity award, granted at $0.00 per share, increases his direct holdings to 78,908 shares. The granted shares are set to vest on June 23, 2026, indicating a com

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:10
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Daxor Corp For: 25 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Daxor Corp, specifically for June 25th. The content is brief, primarily acting as a headline to direct readers to the filing details, and mentions the stock symbol DXR with a -2.91% performance. It also lists various

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:14
Source
Investing.com South Africa
Stock Titan Direct company coverage

DAXOR (DXR) CEO receives 30,000-share equity grant, now holds 243,694

DAXOR CORP CEO Michael Richard Feldschuh was granted 30,000 shares of Daxor Common Stock as compensation, vesting on June 23, 2026. This transaction, reported on Form 4, increased his direct holdings to 243,694 shares, with the granted shares valued at $0.00 each. This equity awa

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Daxor (DXR) director awarded 2,500 stock options at $10.14 strike

Daxor Corp director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. This compensation award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will ves

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 21:41
Source
Stock Titan
Stock Titan Direct company coverage

Daxor (DXR) director granted 2,500 stock options at $10.14

Daxor Corp director Joy S. Goudie was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. The options will vest in three annual installments from June 23, 2026, to June 23, 2028. This grant is contingent on SEC approval of an amendme

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 21:41
Source
Stock Titan
Stock Titan Direct company coverage

DAXOR CORP (DXR) director receives 2,500 stock options at $10.14 strike

DAXOR CORP director Edward Feuer was granted 2,500 stock options as compensation, with an exercise price of $10.14 per share and an expiration date of June 23, 2031. The grant is contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan and will v

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

DAXOR (DXR) director awarded 2,500 stock options at $10.14 strike price

DAXOR CORP director Caleb DesRosiers was granted 2,500 stock options with an exercise price of $10.14 per share, vesting in three annual installments through June 23, 2028. This grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensati

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Daxor (NASDAQ: DXR) investors reelect full board and ratify Bush & Associates as auditor

Daxor Corporation (NASDAQ: DXR) shareholders reelected all six directors—Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers—at their Annual Meeting held on June 23, 2026. Each director received robust support, with "for" votes

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:40
Source
Stock Titan
Quartr Direct company coverage

Daxor (DXR) Q4 2024 earnings summary

Daxor (DXR) reported a strong Q4 2024, with net assets rising to $36.8M and revenue up 116.5% year-over-year. The company achieved cash flow break-even in Q1 2025 and expanded clinical adoption, while also investing in R&D and manufacturing. Daxor anticipates significant growth f

Tone
Positive 73/100
Event
Earnings
Published
19 Jun 2026 19:11
Source
Quartr
Quartr Direct company coverage

Daxor (DXR) Proxy Filing Summary

Daxor (DXR) has scheduled its annual meeting for July 15, 2024, where shareholders will vote on electing six directors and ratifying Citrin Cooperman, LLP as the independent auditor for 2024. The Board recommends approving all director nominees and the auditor. Shareholders of re

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 19:11
Source
Quartr
Quartr Direct company coverage

Daxor (DXR) Q4 2025 earnings summary

Daxor (DXR) achieved a transformative 2025, marked by significant growth in its operating division and a substantial increase in total net assets to over $45.8 million, largely due to a strategic realignment and FDA 510(k) clearance for a new analyzer. The company saw a 45% year-

Tone
Positive 79/100
Event
Earnings
Published
19 Jun 2026 18:40
Source
Quartr
Quartr Direct company coverage

Daxor (DXR) Q2 2024 earnings summary

Daxor (DXR) reported its Q2 2024 earnings, showing an increase in net assets year-over-year but a decrease from the end of 2023. The company experienced an improved net decrease in net assets from operations compared to the prior year, driven by higher sales of BVA system devices

Tone
Positive 66/100
Event
Earnings
Published
19 Jun 2026 18:40
Source
Quartr
TradingKey Direct company coverage

Daxor Corp (DXR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This page provides historical dividend and stock split information for Daxor Corp (DXR). It indicates that Daxor Corp has distributed $0.00 in dividends over the past five years and currently shows no records of past stock splits. The page also includes current stock price data a

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 06:11
Source
TradingKey
TradingKey Direct company coverage

Daxor Corp (DXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Daxor Corp (DXR), detailing its business segments and regional revenue and profit contributions. It notes that relevant financial data for these categories has not yet been disclosed by the company. The page also offer

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Daxor Corp (DXR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Daxor Corp (DXR), listing major individual and institutional holders. It highlights that Joseph Feldschuh UEO is the largest shareholder with 43.82%, followed by other Feldschuh family members. The report also provides a breakdown

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Daxor Corp (DXR) Institutional Confidence

This article from TradingKey provides an overview of Daxor Corp's (DXR) institutional confidence, including its stock performance, key financial metrics, and a list of major shareholders. The data highlights significant institutional holdings and recent changes in shareholder act

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Daxor Corp (DXR), based on analysis from TradingKey. It highlights a target price of USD 22.50 with a 142.98% upside potential, derived from 2 analysts who largely recommend a "Buy" rating for the stock. Key financial data such as ma

Tone
Positive 75/100
Event
Earnings
Published
17 Jun 2026 08:10
Source
TradingKey
Finviz Direct company coverage

DXR - Daxor Corp Stock Price and Quote

Daxor Corp (DXR) is a company specializing in medical instruments and supplies, particularly known for its BVA-100 Blood Volume Analyzer. The article provides a detailed overview of the company's financial performance, recent news releases highlighting new patents, product adopti

Tone
Positive 80/100
Event
Market update
Published
04 Jun 2026 14:40
Source
Finviz
The Manila Times Direct company coverage

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation announced it has received a U.S. patent for a "Remote Blood Volume Monitor." This new technology allows for continuous, remote tracking of a patient's blood volume status using wearable sensors, such as smartwatches, complementing Daxor's existing baseline measu

Tone
Positive 90/100
Event
Market update
Published
04 Jun 2026 02:39
Source
The Manila Times
Stock Titan Direct company coverage

Daxor (DXR) plans June 23, 2026 vote on directors and auditor

Daxor Corporation has scheduled its annual stockholder meeting for June 23, 2026, where shareholders will vote on electing six directors and ratifying Bush & Associates, CPA as the independent auditor for the 2026 fiscal year. The proxy statement details that as of May 20, 2026,

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 20:39
Source
Stock Titan
GuruFocus Direct company coverage

Daxor (DXR) Secures Patent for Innovative Blood Volume Monitoring Technology

Daxor Corp (DXR) has secured a U.S. patent for an innovative system that enables remote monitoring of a patient's overall blood volume using non-invasive optical sensors, potentially integrated into wearable devices. This development is expected to improve patient care outcomes b

Tone
Positive 74/100
Event
Market update
Published
03 Jun 2026 00:09
Source
GuruFocus